The commonly used agents—nivolumab and pembrolizumab (PD-1 antibodies) and atezolizumab (PD-L1 antibody)—operate through similar mechanisms but exhibit distinct response profiles and efficacy patterns in PCa treatment. Here, PDCD1 is linked to posterior cortical atrophy.